Affymetrix Blames 12 Percent Q2 Sales Drop on Weak European Performance, Sales Reorganization | GenomeWeb

This article was first posted on July 22.

By Justin Petrone

Affymetrix last week reported that delays in instrument purchases in Europe and an internal sales reorganization led to a 12 percent decline in second-quarter revenues as a profit swung to a loss.

Still, the firm's management tried to assuage investors last week that all anticipated orders remain in its pipeline, and that any "disruption" associated with sales restructuring has passed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.